Piramal Pharma (NSE:PPLPHARMA) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 28, 2026)


NSE:PPLPHARMA Piramal Pharma Ltd NSE:PPLPHARMA
53 GF Score
Price ₹167.69
GF Value ₹175.28
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Piramal Pharma Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Piramal Pharma's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

NSE:PPLPHARMA vs ZTS: Margin of Safety % (DCF Earnings Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Piramal Pharma's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Piramal Pharma Margin of Safety % (DCF Earnings Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Piramal Pharma's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Piramal Pharma's Margin of Safety % (DCF Earnings Based) falls into.


NSE:PPLPHARMA
53GF Score
Piramal Pharma Ltd NSE:PPLPHARMA
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Piramal Pharma (NSE:PPLPHARMA) Overvalued in 2026?

Based on GuruFocus' analysis, Piramal Pharma stock appears to be undervalued. The current stock price of ₹167.69 is trading 4.3% below its estimated GF Value™ of ₹175.28. GuruFocus considers Piramal Pharma to be Fairly Valued.

Key valuation signals for NSE:PPLPHARMA:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: ₹175.28 vs. price of ₹167.69 (4.3% below fair value)
  • GF Score™: 53/100 with 3 warning signs

No single metric tells the full story. See the NSE:PPLPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Piramal Pharma Business Description

Other Exchanges 543635:India
Address Kamani Junction, LBS Marg, Ground Floor, Piramal Ananta, Agastya Corporate Park, Opposite Fire Brigade, Kurla (West), Mumbai, MH, IND, 400070
Piramal Pharma Ltd is a pharmaceutical company, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and international distribution network. It operates under three business verticals; an integrated contract development and manufacturing (CDMO) business providing Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), biologics, and vaccines among other products; the other two business verticals include a complex hospital generics business, and an India consumer healthcare business, selling over-the-counter products in India. Geographically, the company generates maximum revenue from North America and the rest from Europe, India, Japan, and other markets.
53GF Score

Get the complete analysis for NSE:PPLPHARMA

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹167.69
Price
₹175.28
GF Value